Guy J. Rankl, age 83, of Abbotsford, passed away surrounded by his loving family on Monday, Feb. 10, 2025, under the tender care of Heartland Hospice. A graveside service will be held at a later date.

地舒单抗地舒单抗在临床用于骨质疏松、骨巨细胞瘤、多发性骨髓瘤和实体肿瘤骨转移的治疗。这是目前唯一上市的RANKL抑制剂。它可以与RANK蛋白竞争性结合RANKL蛋白，从而抑制RANKL-RANK-OPG信号通路介导的破骨细胞分化与激活，降低破骨活动， ...

Receptor activator of nuclear factor-κB (RANK) is activated by its ligand, RANKL, an essential molecule for osteoclast development: in the absence of RANKL or RANK, osteoclast differentiation ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

President Trump, in a burst of presidential action unmatched in modern U.S. history, has loosed a flurry of executive orders ...

This study demonstrated that CAG dose-dependently inhibited osteoclast formation in receptor activator of nuclear factor-κB ligand (RANKL)-stimulated bone marrow macrophage (BMMs). Mechanism studies ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.

髋部骨折是老年病人骨质疏松性骨折中常见且严重的骨折类型，在无绝对手术禁忌症的情况下应尽快手术治疗。老年病人髋部骨折的手术目的是：病人术后尽早离床活动，使伤前可生活自理的老年病人恢复正常的行走功能。同时术后尽早下地行走还可避免因卧床导致的废用性骨质疏松 ...

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...